EN DE
Watch Ryvu Therapeutics SA for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Ryvu Therapeutics SA (RVU) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Ryvu Therapeutics SA stock PLN 12.20, price PLN 17.20, that is 29.1% below the price, quality 39 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare PL · ISIN PLSELVT00013

RT Ryvu Therapeutics SA logo Thin data Nov 10, 2026

Ryvu Therapeutics SA

RVU · WAR
Expensive, weak quality

Our calculation puts a fair price 29% below what the stock costs today.

Expensive Growth (revenue 5y +32.2 %/yr in PLN)
Moderate debt
Revenue last quarter 21% below a year ago.
Fair value 12.20 PLN · Overvalued
Quality 39/100
Loss-making · -81.0% net margin (TTM)
Negative free cash flow
Trails peers (1/10)
Narrow moat 6/100 · thin data
Thin data
Estimate
Watch Ryvu Therapeutics SA for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

72.10 PLN 13.76 PLN Fair Value 12.20 PLN Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 13.76 PLN – 72.10 PLN · fair‑value band 9.15 PLN – 15.26 PLN · the 17.20 PLN price screens above the 12.20 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 10, 2026.

Follow Ryvu Therapeutics in your weekly email

Every Wednesday you see whether Ryvu Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally.

Show moreShow less

The company's lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis.

It also develops Dapolsertib (SEL24/MEN1703), a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up for Phase 2 clinical trial for the treatment of diffuse large b-cell lymphoma and acute myeloid leukemia.

In addition, the company's early pipeline candidates include candidates in the areas of kinases, synthetic lethality, immunometabolism, and immuno-oncology.

It has collaborations with BioNTech SE to advance small molecule programs to target immune modulation in cancer and other disease areas; Exelixis Inc. for the development of targeted therapies based on Ryvu's STING agonist technology.

The company was formerly known as Selvita S.A. and changed its name to Ryvu Therapeutics S.A. in October 2019. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.

Stock analysis

Ryvu Therapeutics SA (RVU) currently trades at 17.20 PLN, while our estimate is 12.20 PLN, 29% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 9.15 PLN (bear) to 15.26 PLN (bull), the price of 17.20 PLN sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Ryvu Therapeutics SA reported revenue of 62.3M PLN in FY2025 versus 11.2M PLN in FY2021, a compound +53.6%/yr. Reported net income was −101M PLN in FY2025.

Key figures

Market cap 417M PLN (≈ $107M) Micro · P/S ratio 4.90 · EPS (TTM) −3.07 PLN · Net margin −81.0% · Return on equity −39.5% · Return on assets (EBIT) −32.5% (5-year average) · Operating margin −98.7% · Revenue (TTM) 83.9M PLN.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 42% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −29%, RVU screens richer than that median.

Fair Value

Bear 9.15 PLN Fair Value 12.20 PLN Bull 15.26 PLN
Price 17.20 PLN · Downside -29.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 10
How much profit the company makes from its sales and capital
Quality Growth 30
Are margins and returns getting better?
Cashflow 14
Do the profits arrive as real cash?
Financial strength 36
Debt, balance sheet and risk of trouble
Investment 82
Does it invest with discipline instead of growing at any price?
Low Volatility 64
How calm the share price moves, does not count
Price momentum 18
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 11
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−20.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.2%
Start year 2020 (pandemic). Over 10 years: +4.3% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−231.6% (2020) → −156.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

RVU screens overvalued: fair value 29% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Ryvu Therapeutics SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 39 · Below median
Fair Value upside −29.1% · Below median
Profitability
Return on assets −45.1% · Below median
Net margin (12 months) −81.0% · Bottom 25%
Operating margin (12 months) −98.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −20.8% · Bottom 25%
Balance sheet
Debt / equity 1.31× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 7.74× · Priciest 25%
P/S (12 months) 4.97× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)35 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs RVU
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs RVU
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs RVU
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs RVU
argenx SE ARGX $971.55 $908.40 −7% vs RVU
CSL Limited CSL A$201.68 A$181.40 −10% vs RVU
Moderna, Inc MRNA $250.83 $158.70 −37% vs RVU
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs RVU
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs RVU
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs RVU

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Ryvu Therapeutics SA: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Ryvu Therapeutics SA Fair Value". https://www.fairvalue-calculator.com/stock/RVU

Frequently asked questions

Is Ryvu Therapeutics SA (RVU) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 12.20 PLN versus a price of 17.20 PLN, about 29% lower (overvalued).
What is the fair value of RVU?
Our estimate for Ryvu Therapeutics SA is 12.20 PLN (as of Nov 10, 2026), built from audited fundamentals. The current price: 17.20 PLN.
What is the quality score of RVU?
Ryvu Therapeutics SA has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ryvu Therapeutics SA (RVU)?
Our calculated price target is the estimate of 12.20 PLN (as of Nov 10, 2026). Cautious scenario 9.15 PLN, optimistic scenario 15.26 PLN. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Ryvu Therapeutics SA stock forecast for 2026?
Our estimate puts fair value at 12.20 PLN, about 29% lower versus a price of 17.20 PLN (overvalued). Cautious scenario 9.15 PLN, optimistic scenario 15.26 PLN. The calculation is refreshed regularly with new filings.
What is the revenue of Ryvu Therapeutics SA (RVU)?
Ryvu Therapeutics SA reported trailing-twelve-month revenue of about 83.9M PLN (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Ryvu Therapeutics SA (RVU)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ryvu Therapeutics SA it is 12.20 PLN per share (as of Nov 10, 2026), against a price of 17.20 PLN.
Is Ryvu Therapeutics SA stock overvalued or undervalued in 2026?
As of Nov 10, 2026, RVU trades above its calculated fair value: price 17.20 PLN, fair value 12.20 PLN, a gap of about −29% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RVU?
No. The price is what the market pays today (17.20 PLN); the fair value is what the company's own numbers justify (12.20 PLN). For Ryvu Therapeutics SA the two are 5.00 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Ryvu Therapeutics SA worth?
The market values Ryvu Therapeutics SA at about 417M PLN (market capitalisation, as of Nov 10, 2026). Per share that is 17.20 PLN; our models calculate a fair value of 12.20 PLN per share.
What do the bullish and bearish scenarios say about RVU?
Our models span a range for Ryvu Therapeutics SA: cautious scenario 9.15 PLN, base 12.20 PLN, optimistic 15.26 PLN per share (as of Nov 10, 2026, price 17.20 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Ryvu Therapeutics SA (RVU)?
Balance-sheet figures for Ryvu Therapeutics SA (as of Nov 10, 2026): return on equity −39.5%, debt of 1.31 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is RVU from its 52-week high?
Ryvu Therapeutics SA trades at 17.20 PLN, about 42% below its 52-week high of 29.90 PLN and 25% above the low of 13.76 PLN (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 12.20 PLN is for.
Which stocks are comparable to Ryvu Therapeutics SA?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ryvu Therapeutics SA stock attractive at the current price?
The data as of Nov 10, 2026: price 17.20 PLN, calculated fair value 12.20 PLN (−29%), Quality Score 39/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Ryvu Therapeutics SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ryvu Therapeutics SA (RVU)?
The closing price on Nov 10, 2026 was 17.20 PLN. Our estimate is 12.20 PLN, about 29% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ryvu Therapeutics SA right now?
The price sits above even our optimistic bull case (15.26 PLN). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Ryvu Therapeutics SA

How large is the market capitalisation of Ryvu Therapeutics SA (RVU)?
The market capitalisation of Ryvu Therapeutics SA is 417M PLN (≈ $107M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ryvu Therapeutics SA (RVU)?
The price-to-sales ratio of Ryvu Therapeutics SA is 4.90 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ryvu Therapeutics SA (RVU)?
Earnings per share at Ryvu Therapeutics SA are −3.07 PLN. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Ryvu Therapeutics SA (RVU)?
The net margin of Ryvu Therapeutics SA is −81.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ryvu Therapeutics SA (RVU)?
The return on equity (ROE) of Ryvu Therapeutics SA is −39.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ryvu Therapeutics SA (RVU)?
On an EBIT basis the return on assets of Ryvu Therapeutics SA is −32.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ryvu Therapeutics SA (RVU)?
The operating margin of Ryvu Therapeutics SA is −98.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ryvu Therapeutics SA (RVU)?
Revenue at Ryvu Therapeutics SA is growing −20.8% versus a year earlier (3y avg +17.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Ryvu Therapeutics SA (RVU) generate?
The free cash flow of Ryvu Therapeutics SA is −122M PLN (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Ryvu Therapeutics SA (RVU) carry?
The net debt of Ryvu Therapeutics SA is 14.8M PLN (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Ryvu Therapeutics SA in the live analysis

One click puts Ryvu Therapeutics SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.